Cenexi
Biologics & Sterile Fill-Finish / Small Drug Product OSD Manufacturing – CDMO
Goals & Objectives
Cenexi is a French CDMO originally carved out from Roche. The company began investing in adding steriles capabilities to its existing oral solid dose foundation. Cenexi’s owners engaged That’s Nice to rebrand the CDMO with a brand more reflective of its advancing capabilities and better connect with a new customer base.
Strategic Approach
Cenexi’s strategy was centered on its acquisitions of Big Pharma assets in France and Belgium, highlighting its ability to fill small molecule products in a range of drug delivery formats. This new go-to-market approach melded bright, appealing facility exposure with layers of information on unit capabilities in the company’s expanding OSD and steriles portfolio.
Meeting & Exceeding KPIs
Cenexi’s rebranding was completed in under 6 months, and the company continued its relationship with That’s Nice for 5 years. In this time, That’s Nice supported Cenexi in positioning itself as a genuine alternative to big European steriles CDMOs, culminating in a $120 Million acquisition by Gland Pharma in 2022.
